During 2018 Q4 the big money sentiment increased to 1.33. That’s change of 0.34, from 2018Q3’s 0.99. 16 investors sold all, 50 reduced holdings as Acorda Therapeutics, Inc. ratio is positive. 56 increased holdings while 32 funds amassed holdings. Funds hold 52.19 million shares thus 4.63% more from 2018Q3’s 49.89 million shares.
Commonwealth Of Pennsylvania Public School Empls Retrmt holds 13,535 shs or 0% of its capital. Moreover, Legal And General Gp Public Ltd has 0% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Susquehanna Group Llp stated it has 30,966 shs. The Japan-based Daiwa Securities Grp Inc has invested 0% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Systematic L P, a New Jersey-based fund reported 67,045 shs. Secor Advsr L P, New York-based fund reported 12,683 shs. The United Kingdom-based Pictet Asset Ltd has invested 0.01% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). State Bank Of Ny Mellon Corp accumulated 0% or 482,346 shs. Quantitative Management Limited Company holds 0.01% or 12,300 shs in its capital. New York-based Bnp Paribas Arbitrage Sa has invested 0% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). 784,271 were accumulated by Clearbridge Invs Ltd Liability Corp. Acadian Asset Mgmt Ltd Liability holds 584,747 shs or 0.05% of its capital. Diamond Hill Cap reported 0% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Pinebridge Invests Lp holds 0.02% in Acorda Therapeutics, Inc. (NASDAQ:ACOR) or 45,527 shs. Convergence Inv Ptnrs Limited Liability Corporation reported 0.06% in Acorda Therapeutics, Inc. (NASDAQ:ACOR).

Acorda Therapeutics, Inc. registered $35.74 million net activity with 0 insider purchases and 27 insider sales since October 2, 2018. Hindman Andrew A. sold $15,478 worth of Acorda Therapeutics, Inc. (NASDAQ:ACOR) on Monday, December 3. COHEN RON sold $74,554 worth of Acorda Therapeutics, Inc. (NASDAQ:ACOR) or 3,620 shs on Monday, December 3. On Monday, December 3 $106,737 worth of Acorda Therapeutics, Inc. (NASDAQ:ACOR) was sold by Sabella Lauren M. On Monday, December 3 the insider Wasman Jane sold $62,947. $51,232 worth of Acorda Therapeutics, Inc. (NASDAQ:ACOR) was sold by LAWRENCE DAVID on Monday, December 3. On Monday, November 26 Randall Lorin sold $38,034 worth of Acorda Therapeutics, Inc. (NASDAQ:ACOR) or 1,904 shs.

On May, 1 Acorda Therapeutics, Inc. (NASDAQ:ACOR)’s earnings release is expected by WallStreet, Faxor reports. This year’s earnings per share analyst estimate is expected to be $-0.82. That is 355.56 % down compareed to $-0.18 earnings per share for last year. -300.00 % negative EPS growth is what analysts predict. $0.41 earnings per share was announced for previous quarter. ACOR hit $13.29 during the last trading session after $0.12 change.Acorda Therapeutics, Inc. has volume of 432,357 shares. Since April 1, 2018 ACOR has declined 39.92% and is downtrending. ACOR underperformed by 44.29% the S&P 500.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Ratings Coverage

In total 4 analysts cover Acorda Therapeutics (NASDAQ:ACOR). “Buy” rating has 1, “Sell” are 1, while 2 are “Hold”. 25% are bullish. 6 are the (NASDAQ:ACOR)’s analyst reports since October 5, 2018 according to StockzIntelligence Inc. On Friday, February 15 the rating was maintained by Cantor Fitzgerald with “Hold”. The stock rating was maintained by H.C. Wainwright with “Buy” on Thursday, February 21. On Friday, March 1 H.C. Wainwright maintained the shares of ACOR in report with “Buy” rating. On Friday, October 5 Stifel Nicolaus maintained Acorda Therapeutics, Inc. (NASDAQ:ACOR) rating. Stifel Nicolaus has “Hold” rating and $19 target. On Tuesday, December 11 the rating was downgraded by Goldman Sachs to “Sell”.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States.The firm is worth $633.05 million. The firm markets Ampyra , an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.18.72 is the P/E ratio. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.

For more Acorda Therapeutics, Inc. (NASDAQ:ACOR) news brought out briefly go to: Nasdaq.com, Nasdaq.com, Globenewswire.com, Benzinga.com or Nasdaq.com. The titles are as follows: “Acorda Therapeutics (ACOR) Gains But Lags Market: What You Should Know – Nasdaq” brought out on March 15, 2019, “Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija – Nasdaq” on September 14, 2018, “Glancy Prongay & Murray LLP Announces Investigation on Behalf of Acorda Therapeutics, Inc. Investors (ACOR) – GlobeNewswire” with a publish date: March 05, 2019, “Acorda’s Prospects Remain Dubious Despite Inbrija Approval, Says Bearish Raymond James (NASDAQ:ACOR) – Benzinga” and the last “Acorda (ACOR) Down 6% Since Last Earnings Report: Can It Rebound? – Nasdaq” with publication date: March 16, 2019.